 |
| |
 |
| |
 |
| |
 |
| |
 |
| _____________________________________________________________________________________________________________________ © 2005-11 All Rights Reserved. NOD Pharmaceuticals, Inc. |
SHANGHAI, Oct. 10, 2010 -- NOD Pharmaceuticals Inc. announced that Chinese State Patent Office
has allowed the patent application for its nano-particle oral delivery or NOD technology.
NOD technology is a highly efficient approach to incorporate peptides or proteins into bio-adhesive
nano-particles to enable oral delivery of drugs otherwise administered as injections. NOD technology is
a platform technology that can be applied to many macromolecular drugs such as insulin, interferon,
growth hormone, exenatide, heparin and more.
Currently, an oral insulin formulation, the first candidate developed with NOD technology, is entering
phase I clinical studies in China.
"This patent allowance for NOD tech is a key milestone for NOD", quoted from William Lee, CEO.
"Considering that our first product candidate is in clinical trial in China. This patent with other
applications form the core competence for NOD and demonstrates the innovative capability at NOD.”
For more information, please contact:
William Lee, Ph.D., CEO
Phone: +86-21-6194-0758
Email: info@nodpharm.com
Notes for Editors
About NOD Pharmaceuticals
NOD Pharmaceuticals, Inc. is a development stage biotech company and emerging leader in innovative
delivery for biopharmaceuticals. NOD uses patented platform technology, nano-particle oral delivery or
NOD technology, to develop oral formulations for biopharmaceuticals, including insulin, exenatide,
interferon, human growth hormone and more.
More information can be found at http://www.nodpharm.com
SOURCE NOD Pharmaceuticals, Inc.
has allowed the patent application for its nano-particle oral delivery or NOD technology.
NOD technology is a highly efficient approach to incorporate peptides or proteins into bio-adhesive
nano-particles to enable oral delivery of drugs otherwise administered as injections. NOD technology is
a platform technology that can be applied to many macromolecular drugs such as insulin, interferon,
growth hormone, exenatide, heparin and more.
Currently, an oral insulin formulation, the first candidate developed with NOD technology, is entering
phase I clinical studies in China.
"This patent allowance for NOD tech is a key milestone for NOD", quoted from William Lee, CEO.
"Considering that our first product candidate is in clinical trial in China. This patent with other
applications form the core competence for NOD and demonstrates the innovative capability at NOD.”
For more information, please contact:
William Lee, Ph.D., CEO
Phone: +86-21-6194-0758
Email: info@nodpharm.com
Notes for Editors
About NOD Pharmaceuticals
NOD Pharmaceuticals, Inc. is a development stage biotech company and emerging leader in innovative
delivery for biopharmaceuticals. NOD uses patented platform technology, nano-particle oral delivery or
NOD technology, to develop oral formulations for biopharmaceuticals, including insulin, exenatide,
interferon, human growth hormone and more.
More information can be found at http://www.nodpharm.com
SOURCE NOD Pharmaceuticals, Inc.
Press Release
| Chinese Patent Allowed for NOD Tech |
 |  |  |
-Innovation Delivered